Tebes Stephen J, Sayer Robyn A, Palmer James M, Tebes Christine C, Martino Martin A, Hoffman Mitchel S
Department of Obstetrics and Gynecology, University of South Florida Tampa, FL 33606, USA.
Gynecol Oncol. 2007 Sep;106(3):482-7. doi: 10.1016/j.ygyno.2007.04.006. Epub 2007 Jun 27.
This study aims to identify favorable preoperative characteristics and examine the impact of secondary cytoreductive surgery on survival for patients with recurrent epithelial ovarian carcinoma.
Patients who underwent cytoreductive surgery for recurrent epithelial ovarian cancer were identified in our surgical database for the period 1988-2004. Patient charts were reviewed and data collected regarding patient demographics, surgical management, preoperative evaluation, perioperative complications, and oncologic outcome.
Eighty-five patients met eligibility criteria. Preoperative factors that correlated with improved survival were disease-free interval of greater than 12 months (p<0.01) and residual disease after primary surgery of <2 cm (p<0.02). Other preoperative factors evaluated but not found significant included radiographic findings, physical findings, previous histology, stage, grade, previous chemotherapy, prior recurrence, and serum CA-125 level. Optimal resection to <1 cm residual disease was achieved in 86% of patients who had secondary cytoreduction. Small bowel and colon resection for cytoreduction occurred in 7% and 51% of patients, respectively. Operative complications occurred in 14% and postoperative complications occurred in 21% of patients. The median survival of patients who were optimally cytoreduced to <1 cm was 30 months compared to 17 months for patients with residual disease>or=1 cm (p<0.05). Operative factors that were evaluated and did not significantly effect survival were location of recurrence, presence of ascites, and extent of recurrence. Recurrent or progressive disease occurred in 75% of patients during follow-up.
When selecting patients for secondary cytoreduction, the most significant preoperative factors are disease-free interval and success of a prior cytoreductive effort. Once secondary cytoreductive surgery is attempted, the most important factor for improved survival is optimal cytoreduction. Of equal importance is counseling regarding the significant risk for bowel surgery, colostomy, and complications.
本研究旨在确定复发性上皮性卵巢癌患者有利的术前特征,并探讨二次减瘤手术对其生存的影响。
在我们1988 - 2004年的手术数据库中识别接受复发性上皮性卵巢癌减瘤手术的患者。回顾患者病历并收集有关患者人口统计学、手术管理、术前评估、围手术期并发症和肿瘤学结果的数据。
85例患者符合入选标准。与生存改善相关的术前因素为无病间期大于12个月(p<0.01)以及初次手术后残留病灶<2 cm(p<0.02)。评估的其他术前因素未发现有显著意义,包括影像学检查结果、体格检查结果、既往组织学、分期、分级、既往化疗、既往复发情况以及血清CA - 125水平。86%接受二次减瘤的患者实现了残留病灶<1 cm的最佳切除。分别有7%和51%的患者因减瘤进行小肠和结肠切除。14%的患者发生手术并发症,21%的患者发生术后并发症。残留病灶最佳减瘤至<1 cm的患者中位生存期为30个月,而残留病灶≥1 cm的患者为17个月(p<0.05)。评估的对生存无显著影响的手术因素为复发部位、腹水情况和复发范围。75%的患者在随访期间出现复发或疾病进展。
在选择二次减瘤手术的患者时,最重要的术前因素是无病间期和既往减瘤手术的成功情况。一旦尝试进行二次减瘤手术,则改善生存的最重要因素是最佳减瘤。同样重要的是就肠道手术、结肠造口术和并发症的重大风险进行咨询。